Clinical trial · Interventional
TACE With Immune Agents for Angiogenesis in Hepatocellular Carcinoma
Clinical Study on TACE Combined With Immune Agents for Inhibiting Tumor Angiogenesis in Hepatocellular Carcinoma
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
This study investigates the clinical efficacy and safety of transarterial chemoembolization (TACE) combined with the immune agent nivolumab compared to TACE alone for treating hepatocellular carcinoma (HCC). The study aims to determine if the combination therapy can more effectively inhibit tumor angiogenesis, improve clinical benefit rates, and prolong survival, while maintaining a high safety profile.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Hepatocellular Carcinoma (HCC) | Hepatocellular Carcinoma | ONTOLOGY_EXACT | 0.85 |
Interventions
Interventions (2)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Nivolumab | Combination Product | — | UNRESOLVED |
| Transarterial Chemoembolization (TACE) | Procedure | — | UNRESOLVED |
Design
Arms and outcomes
Arms (2)
- type
- EXPERIMENTAL
- label
- TACE combined with Nivolumab
- description
- Patients received TACE procedure. Additionally, hepatic artery infusion therapy with nivolumab was performed.
- interventionNames
- Combination Product: Nivolumab
- Procedure: Transarterial Chemoembolization (TACE)
- type
- ACTIVE_COMPARATOR
- label
- TACE Alone
- description
- Patients received TACE procedure alone.
- interventionNames
- Procedure: Transarterial Chemoembolization (TACE)
Primary outcomes (2)
- measure
- Objective Response Rate (ORR)
- timeFrame
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * Age \>18 years; * Diagnosis of HCC according to the Diagnosis and Treatment Guidelines for Primary Liver Cancer (2024 Edition), confirmed by pathological examination; * Barcelona Clinic Liver Cancer (BCLC) stages A, B, and C, with non-resectable tumors; * Liver function graded as Child-Pugh A or B; * At least one measurable lesion according to the Response Evaluation Criteria in Solid Tumors (RECIST) 1.1; * Eastern Cooperative Oncology Group (ECOG) performance status score of 0-2; * No severe hematologic abnormalities or immune deficiencies; * Expected survival time \>6 months. Exclusion Criteria: * Recurrent liver cancer or metastatic cancer from other organs; * Previous treatment with other antitumor therapies, including surgery, radiotherapy, chemotherapy, targeted therapy, or immunotherapy; * History of other malignant tumors; * Pregnant or lactating women; * Human immunodeficiency virus (HIV) infection; * Severe cardiovascular, pulmonary, cerebral, or renal diseases; * Active bleeding or coagulopathy outside the liver; * Enrollment in another clinical trial or participation in a clinical trial within one month prior to admission; * Psychiatric disorders or unstable mental status; * Allergic reactions to the study drugs; * Severe gastrointestinal diseases, such as active ulcers, or other conditions affecting drug absorption.
References
Publications (0)
Data not yet available